Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Paraganglioma is a rare neuroendocrine tumor arising from chromaffin cells in the adrenal medulla or sympathetic ganglia. Its market dynamics are influenced by several factors, ranging from prevalence and diagnosis to treatment options and research advancements.
The market for Paraganglioma is characterized by its low prevalence, making it a niche segment within the broader oncology market. Despite its rarity, the incidence rates are gradually increasing, necessitating a closer look at the market dynamics to cater to the evolving patient needs.
Diagnostic technologies developments highly affect the market. Technologically advanced imaging methods, PET scans and genetic assays are crucial for an early and precise diagnosis. On account of the greater availability of these technologies, the market for Paraganglioma is set to grow.
The treatment of Paraganglioma includes surgical, radiotherapy and pharmacotherapy. Surgical resection is still the main curative approach, but market dynamics change with the development of targeted therapies and new treatment modalities. The change is prompted by an increasing insight on the genetic nature of Paraganglioma.
Genetical factors are the key in evolution of Paraganglioma. Trends in the market are moving towards personalized medicine where targeted therapies are formulated to treat specific genetic mutations which are related to Paraganglioma. This tendency and making the future of the market was not only increasing the effectiveness of the treatment.
Patients and healthcare professionals are aware of the dynamics of the market. Education and support initiatives are being contributed to by advocacy groups and patient organization. Influencing treatment-seeking behavior is the possibility of the increase in the awareness which may result in early detection as well as the informed patients.
However, there are market penetration challenges in the Paraganglioma treatments. Poor knowledge of healthcare providers together with the rarity of the disease is a barrier to timely diagnosis and correct treatment. This is an important problem to be resolved, for the ongoing development of the Paraganglioma market.
On-going research activities and clinical trials are essential to the market dynamics. Pharmaceutical organizations and research institutes are putting funds in knowledge of the molecular pathways of Paraganglioma as they want to come up with new therapeutic interventions. The market is sensitive to the advances of research, which in turn, may change the treatment paradigms.
The Paraganglioma market cut across geographical boundaries. International cooperations and exchange of informations help in the creation of common response to this rare tumor. Interconnected nature of Paraganglioma research and treatment is stressed when the changes in one part of the world influence the overall market trends.
Paraganglioma Market Highlights:
Paraganglioma Market Scenario:The paraganglioma market is projected to reach USD 3,264 Million by 2030 at 1.00% CAGR during the forecast period 2022-2030. A paraganglioma or glomus tumors is a rare type of cancer occurs in a variety of places in the head and neck. The tumor begins in certain nerve cells that are distributed throughout the body. Paragangliomas affect at any age and over half of the paragangliomas appear in the temporal bone. Similar to other types of cancer, paragangliomas is very difficult to diagnose in early stages as the tumor is often slow growing and noncancerous (benign). However, it can invade other/ nearby organ and part of the body, and become cancerous and spread distantly. Though a number of diagnostic and therapeutic treatments are available in the market, none of them are that effective for the treatment and diagnostic. According to the research carried out by Florida Hospital System (2014), 1-2 patient in a million develops paragangliomas. According to cancer research the UK in 2012, globally over 14.1 million of new cancer cases were registered. The treatment for all types of cancer are nearly similar, thus, increasing prevalence of cancer has boosted the development of the new treatments. Increasing number of patients suffering from paragangliomas and continuous advances in the treatment have driven the growth of the market. Additionally, deteriorating lifestyle due to alcoholism and smoking, increasing healthcare expenditure, and increasing government support for research & development have fuelled the market growth. A number of treatment are available in the market, however, nearly all the treatment show some or other adverse effects on the body. Additionally, high cost of the treatment and side effects of the therapy may slow the growth of the market during the forecasted period.
 Figure 1- Market Synopsis of the Global Paraganglioma Market Research, by Region, 2016 (%) 
Sources- WHO, cancer research UK, American Cancer Society
Segmentation
The global paraganglioma market is segmented on the basis of types, treatment, and end users.
On the basis of types, the market is segmented into caroid paraganglioma, cervical paraganglioma, jugular paraganglioma, secretory paraganglioma, temporal paraganglioma, vagal paraganglioma, and others.
On the basis of the treatment, the market is categorized into therapeutic treatment and diagnostic treatment. The therapeutic treatment is further segmented into surgery, embolization, and radiotherapy. The embolization is further categorized into liquid embolic agents, sclerosing agents, particulate embolic agents, and others. The radiotherapy is sub-segmented into external beam radiation therapy, brachytherapy, and unsealed source radiotherapy. The diagnostic treatments are further segmented into CT scans, MRI, angiography, blood test, and others.
On the basis of the end users, the market is segmented into hospital & clinics, ambulatory care centers, and others.Â
Regional Analysis
The Americas account for the major share of the global paraganglioma market owing to the increasing prevalence of paragangliomas, well-developed technology and increasing government support for research & development. Moreover, high healthcare expenditure and changing lifestyle have fuelled the growth of the Americas paraganglioma market. The concentration of major players in this region is likely to support the growth of the market during the forecasted period.
Europe holds the second largest paraganglioma market, which is followed by Asia Pacific. Availability of the funds for research & development and strong government support have driven the market growth. Asia Pacific is the fastest growing paraganglioma market owing to the increasing prevalence of cancer, rapidly developing the economy and increasing government support.
On the other hand, the Middle East & Africa hold the least share of the market due to poor political conditions in Africa and limited availability of funds and availability of medical facilities. The Middle East dominates the Middle East & Africa Paraganglioma market due to the presence of well-developed countries like Kuwait, Qatar, Oman and South Arabia. Whereas, Africa region is expecting a healthy growth due to the presence of huge opportunity for the development of the market.
Market Assessment 
Sources- WHO, cancer research UK, American Cancer Society
Â
Key Players in Global Paraganglioma Market
Some of key the players in the market are Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (U.S.), Amgen, Inc. (U.S.), Â Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), AbbVie Inc. (U.S.), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Sanofi (France), Merck & Co., Inc. (U.S.), Immunomedics (U.S.),and Oncomed Pharmaceuticals (U.S.).
Intended Audience
- Pharmaceutical Companies
- Government and private research companies
- Research and Development (R&D) Companies
- Drug Manufacturers and Suppliers
- Medical Research Laboratories
Â
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
